Alnylam Pharmaceuticals (ALNY)
(Delayed Data from NSDQ)
$272.64 USD
-4.69 (-1.69%)
Updated Aug 23, 2024 03:59 PM ET
After-Market: $272.59 -0.05 (-0.02%) 7:58 PM ET
3-Hold of 5 3
F Value C Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (TTM)
The company's trailing twelve month (TTM) Cash from Investing is the sum of the company's past 12 months cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
ALNY 272.64 -4.69(-1.69%)
Will ALNY be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for ALNY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for ALNY
Alnylam (ALNY) Amvuttra & Givlaari Fuel Revenues Amid Competition
Is First Trust NYSE Arca Biotechnology ETF (FBT) a Strong ETF Right Now?
ALNY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Should You Invest in the First Trust NYSE Arca Biotechnology ETF (FBT)?
AGIO Q2 Earnings Lag, Stock Down on Missing Pediatric Study Goal
Alnylam (ALNY) Up as Q2 Earnings Beat on Collaboration Revenues
Other News for ALNY
BridgeBio: PDUFA Date Expected In November 2024 Could Shift Momentum
SIZE: A Good Mid-Cap ETF, Yet Not The Best
Buy Rating Affirmed for Alnylam Pharmaceuticals on Strong Amvuttra Trial Results and Robust Market Potential
Goldman upgrades Alnylam to Buy ahead of 'fundamental re-rating'
Goldman Sachs gets more bullish on Alnylam, upgrades shares